<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.98149</article-id><article-id pub-id-type="publisher-id">ACM-31769</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190800000_98699668.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  RLIP76在肿瘤靶向治疗的研究进展
  Research Progress of RLIP76 in Targeted Therapy of Tumor
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>东</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>毛</surname><given-names>艺</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>雅楠</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>岳</surname><given-names>少宇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>蚌埠医学院，临床医学院，安徽 蚌埠</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>08</month><year>2019</year></pub-date><volume>09</volume><issue>08</issue><fpage>978</fpage><lpage>985</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    过去20年里，全球癌症发病率处于快速上升阶段，癌症的治疗一直是医学界的难题。目前常规化疗药物的主要缺点是选择性较低，对肿瘤的治疗效果较差。具有高度特异性的靶向治疗对患者的治疗效果更好，不良反应更少。靶向治疗的开发具有良好的前景。RLIP76是一种多药转运体和抗凋亡蛋白，是化疗耐药和癌细胞信号转导的关键分子之一。RLIP76在癌细胞中存在固有的过度表达，而正常细胞对RLIP76的依赖性相对较小，这为认识RLIP76作为一种独特的抗癌靶点的潜力提供了证据。在许多癌细胞系和异种移植物中，通过抑制RLIP76触发凋亡通路，一致观察到的退化结果为RLIP76在临床上作为一种新的治疗药物提供了一定的思路。
    In the past 20 years, the global incidence of cancer has been rising rapidly and the treatment of cancer has always been a challenge for the medical community. At present, the main shortcomings of conventional chemotherapy drugs are low selectivity and poor therapeutic effect on tumors. Targeted therapy with high specificity has a better therapeutic effect on patients with fewer ad-verse reactions. The development of targeted therapy has a good prospect. RLIP76 is a multidrug transporter and anti-apoptotic protein, which is one of the key molecules in chemotherapy re-sistance and signal transduction of cancer cells. RLIP76 is inherently overexpressed in cancer cells, while normal cells have relatively little dependence on RLIP76, which provides evidence for ac-knowledging RLIP76’s potential as a unique anticancer target. In many cancer cell lines and xeno-grafts, by inhibiting RLIP76 to trigger the apoptotic pathway, the consistently observed degradation results provide some ideas for RLIP76 as a new therapeutic drug in clinical practice. 
  
 
</p></abstract><kwd-group><kwd>RLIP76，肿瘤，靶向治疗，转运，凋亡, RLIP76</kwd><kwd> Tumor</kwd><kwd> Targeted Therapy</kwd><kwd> Transport</kwd><kwd> Apoptosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>RLIP76在肿瘤靶向治疗的研究进展<sup> </sup></title><p>刘东，毛艺，马雅楠，岳少宇</p><p>蚌埠医学院，临床医学院，安徽 蚌埠</p><p><img src="//html.hanspub.org/file/13-1571012x1_hanspub.png" /></p><p>收稿日期：2019年7月29日；录用日期：2019年8月13日；发布日期：2019年8月20日</p><disp-formula id="hanspub.31769-formula9"><graphic xlink:href="//html.hanspub.org/file/13-1571012x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>过去20年里，全球癌症发病率处于快速上升阶段，癌症的治疗一直是医学界的难题。目前常规化疗药物的主要缺点是选择性较低，对肿瘤的治疗效果较差。具有高度特异性的靶向治疗对患者的治疗效果更好，不良反应更少。靶向治疗的开发具有良好的前景。RLIP76是一种多药转运体和抗凋亡蛋白，是化疗耐药和癌细胞信号转导的关键分子之一。RLIP76在癌细胞中存在固有的过度表达，而正常细胞对RLIP76的依赖性相对较小，这为认识RLIP76作为一种独特的抗癌靶点的潜力提供了证据。在许多癌细胞系和异种移植物中，通过抑制RLIP76触发凋亡通路，一致观察到的退化结果为RLIP76在临床上作为一种新的治疗药物提供了一定的思路。</p><p>关键词 :RLIP76，肿瘤，靶向治疗，转运，凋亡</p><disp-formula id="hanspub.31769-formula10"><graphic xlink:href="//html.hanspub.org/file/13-1571012x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/13-1571012x7_hanspub.png" /> <img src="//html.hanspub.org/file/13-1571012x8_hanspub.png" /></p></sec><sec id="s3"><title>1. RLIP76简介</title><p>Ral-相互作用蛋白76 (RLIP76, Ral-interacting protein 76)是一种76 kD的剪接体蛋白，其N末端调节细胞扩散和迁移 [<xref ref-type="bibr" rid="hanspub.31769-ref1">1</xref>]，位于人类18p11.3染色体上由一个含有11个外显子和9个内含子的基因编码 [<xref ref-type="bibr" rid="hanspub.31769-ref2">2</xref>]，又称Ral A结合蛋白1 (Ral A binding protein 1, RALBP1)。RLIP76在包括肝脏在内的大多数人体组织中表达，还在心脏、肺、肌肉、肾脏、红细胞和白细胞以及大多数人类肿瘤细胞系表达。RLIP76是一种多功能膜蛋白，可将谷胱甘肽与亲电化合物和其他异种生物制剂(包括化疗药物)的偶联物运出细胞 [<xref ref-type="bibr" rid="hanspub.31769-ref3">3</xref>]。这种蛋白在肺癌、卵巢癌和黑色素瘤中过度表达 [<xref ref-type="bibr" rid="hanspub.31769-ref4">4</xref>]。该蛋白还可与Ral结合，参与有丝分裂纺锤体功能、网格蛋白依赖性内吞 [<xref ref-type="bibr" rid="hanspub.31769-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.31769-ref6">6</xref>]，并激发GTP酶活化蛋白活性。它存在于整个细胞、细胞膜、细胞质和细胞核中，并在这些细胞间随着压力的变化而移动，RLIP76在恶性细胞中经常过量表达，对恶性肿瘤细胞的生长、浸润、转移以及对药物反应起关键作用 [<xref ref-type="bibr" rid="hanspub.31769-ref7">7</xref>]，其中可通过调控促凋亡氧化脂质副产物的细胞浓度，选择性地在癌细胞中发挥显著的抗凋亡作用 [<xref ref-type="bibr" rid="hanspub.31769-ref8">8</xref>]。</p></sec><sec id="s4"><title>2. RLIP76的生理功能</title><p>RLIP76是一种广泛表达的多功能蛋白，在应激防御、转运、抗凋亡、信号转导等方面发挥重要作用。RLIP76的生理功能之一是通过介导花生四烯酸氧化降解形成的亲电化合物与谷胱甘肽的偶联物(GS-E, glutathione-electrophile conjugates)的外排，调节氧化脂质代谢的亲电中间体细胞内浓度，从而控制细胞内促凋亡氧化脂质副产物和其他异种生物制剂(如化疗药物)的浓度，其中GS-E包括白三烯和4HNE-GSH偶联物。RLIP76介导两亲性化疗药物，如蒽环类药物和长春碱的转运，以及氧化代谢过程中产生的GS-E，赋予了这种多功能蛋白在抵抗机制中发挥核心作用的功能，以抑制化疗药物引起的细胞凋亡。RLIP76还涉及与许多内外部应激源相互作用，包括氧化应激、热休克和辐射 [<xref ref-type="bibr" rid="hanspub.31769-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.31769-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.31769-ref11">11</xref>]。虽然RLIP76涉及许多其他活动，但在本节中我们将讨论RLIP76的三个主要功能。</p><sec id="s4_1"><title>2.1. 转运作用</title><p>RLIP76是一种主动转运结构不同的化合物的非ABC类ATP依赖转运体。自从发现RLIP76的S-二硝基苯谷胱甘肽(dinitrophenyl S-glutathion, DNP-SG)ATP酶活性以来，许多研究表明RLIP76转运功能的重要性，尤其是对化疗药物和抗癫痫药物 [<xref ref-type="bibr" rid="hanspub.31769-ref12">12</xref>] 的转运功能，以及亲电偶联物 [<xref ref-type="bibr" rid="hanspub.31769-ref3">3</xref>] 的转运功能(图1)。其底物范围从弱阳离子化合物到亲电性谷胱甘肽结合物等阴离子代谢物 [<xref ref-type="bibr" rid="hanspub.31769-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.31769-ref13">13</xref>] 包括：阿霉素(doxorubicin, DOX)、长春碱(vinblastine, VBL)、长春新碱(vincristine, VCR)、长春瑞滨(vinorelbine, VRL)、水仙碱、舒尼替尼和索拉非尼。RLIP76具有广泛的底物特异性，广泛存在在于不同组织中，特别是在肿瘤组织中过度表达，这使得RLIP76成为内、外源代谢产物的重要调节因子。</p><p>RLIP76的一个显著特征是它的传输作用不需要完整的RLIP76。RLIP76的N端和C端分别纯化并重组成人工脂质体后，具有相似的转运活性，说明蛋白水解得到的多肽可以重新构建完整的转运功能。虽然两种肽均表现出ATP酶活性，但N末端的活性均大于C末端，但两种肽都不能单独完成转运功能 [<xref ref-type="bibr" rid="hanspub.31769-ref14">14</xref>]。当底物存在时，肽的ATP酶活性增加了2倍。这种转运活性与温度有关，并且对渗透性很敏感，ATP水解和转运之间呈1:1化学计量的关系。当ATP被不可水解的类似物取代时，亚甲基ATP缺乏转运功能，说明转运依赖ATP。RLIP76作为GS-E药物转运体在进一步的RLIP76−/−老鼠中的研究被证实，由于组织RLIP76的缺失，脂质氢过氧化物、醛、烷烃的积累增加了2~7倍 [<xref ref-type="bibr" rid="hanspub.31769-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.31769-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.31769-ref15">15</xref>]。与此同时，GS-E和蒽环霉素的总转运活性损失超过80%，这种损失转化为对异种生物毒素，包括RLIP76的底物传统化疗药物，以及代谢成GS-E的其他烷基化剂和铂配合物，具有更大的敏感性。将RLIP76−/−老鼠组织制备的膜囊泡用于测试运输功能，结果显示大约损失80%的运输活动，将纯化的RLIP76脂质体导入这些囊泡后，该活性完全恢复 [<xref ref-type="bibr" rid="hanspub.31769-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.31769-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.31769-ref16">16</xref>]。另抑制RLIP76的运输功能导致在裸鼠中的人肾癌异种移植物消退 [<xref ref-type="bibr" rid="hanspub.31769-ref17">17</xref>]。</p><p>图1. RLIP76的细胞转运功能</p></sec><sec id="s4_2"><title>2.2. 防止热休克和氧化应激</title><p>RLIP76除了作为膜转运蛋白外，还可作为各种应激反应蛋白的调控蛋白。在正常生理条件下，RLIP76存在于热休克因子-1 (Heat Shock Factor-1, HSF-1)、微管蛋白、热休克蛋白90 (Heat Shock Protein 90, HSP90)和Ral的复合物中 [<xref ref-type="bibr" rid="hanspub.31769-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.31769-ref19">19</xref>]。HSP90是由于化学或辐射损伤而释放的，两者都会导致氧化应激和HSF-1迁移到细胞核，导致大量热休克蛋白的转录上调。研究还表明，热休克可高度激活Ral信号转导通路，释放HSF-1和允许其进入核内 [<xref ref-type="bibr" rid="hanspub.31769-ref18">18</xref>]。因此，RLIP76修饰HSF-1用来抑制热休克蛋白的翻译。RLIP76−/−老鼠组织内热休克蛋白的含量的升高也支持了这个观点 [<xref ref-type="bibr" rid="hanspub.31769-ref20">20</xref>]。</p><p>RLIP76的诱导是在已知的热休克蛋白或抗氧化酶出现之前，对热休克或氧化剂的一种早期反应 [<xref ref-type="bibr" rid="hanspub.31769-ref10">10</xref>]。经应激休克预处理的细胞，迁移GS-HNE的速率提高3倍。而GS-HNE的外溢增加可被细胞表面的RLIP76抗体阻断，证实GS-HNE由RLIP76运输。应激预处理的具有诱导hGST 5.8和RLIP76细胞通过抑制c-Jun氨基末端激酶(c-Jun N-terminal kinase, JNK)和天冬氨酸蛋白水解酶(cysteinyl aspartate specific proteinase-3, caspase-3)的持续活化，获得对4-羟基壬烯酸(4-hydroxy-t-nonenal, 4HNE)和H<sub>2</sub>O<sub>2</sub>介导的凋亡的抗性。通过在细胞表面涂层RLIP76 IgG，抑制GS-HNE的外排，消除了应激预处理对H<sub>2</sub>O<sub>2</sub>或4HNE诱导凋亡的保护作用。这些结果表明，细胞通过代谢和排除4HNE获得了对凋亡的抗性，细胞内GS-HNE和内源性GS-E浓度调节应激介导的信号通路 [<xref ref-type="bibr" rid="hanspub.31769-ref21">21</xref>]。</p></sec><sec id="s4_3"><title>2.3. 防止辐射毒性</title><p>活性氧(ROS)的生成是高能辐射以及热休克和氧化剂暴露的常见途径，RLIP76可能具有抗辐射的能力。之前的研究表明接纳包含蛋白脂质体的RLIP76的培养细胞将增加细胞RLIP76水平以及阿霉素耐药性。在Rit Vatsyayan的研究 [<xref ref-type="bibr" rid="hanspub.31769-ref21">21</xref>] 中，通过测定RLIP76增加对辐射敏感性的影响来验证这一假设，将重建的含有RLIP76脂质体的纯化小细胞肺癌细胞(H182和H1618)暴露前在500 cGy单一剂量的辐射。辐射后，再接种到培养基，连续传代直至培养细胞达到5 &#215; 10<sup>5</sup>个细胞/毫升的密度，每隔24小时测定一次。与对照细胞相比，RLIP76富集的细胞具有更强的抗辐射能力。这些结果表明，脂质过氧化反应中间体形成的GS-E的积累对辐射毒性有显著的作用，这些副产物的外排增加了细胞对辐射的抵抗力 [<xref ref-type="bibr" rid="hanspub.31769-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.31769-ref22">22</xref>]。</p></sec></sec><sec id="s5"><title>3. RLIP76与肿瘤的联系</title><p>RLIP76对恶性肿瘤细胞的生长、浸润、转移以及对药物反应起重要作用。RLIP76在多种肿瘤组织均有上调 [<xref ref-type="bibr" rid="hanspub.31769-ref17">17</xref>]，包括肺癌、膀胱癌、卵巢癌、肾癌、脑膜瘤、食管癌。郭晓峰等 [<xref ref-type="bibr" rid="hanspub.31769-ref23">23</xref>] 在食管鳞癌的研究表明，RLIP76在食管鳞癌组织中的阳性表达率明显高于正常食管组织(P &lt; 0.05)，与潘海霞等 [<xref ref-type="bibr" rid="hanspub.31769-ref24">24</xref>] 在细胞肺癌中的研究结果相似。Wang等 [<xref ref-type="bibr" rid="hanspub.31769-ref25">25</xref>] 的研究表明抑制RLIP76可以控制胃癌的浸润程度；郭晓峰等人在食管鳞癌组织中表达与浸润深度有关的结果，表明RLIP76可以促进恶性肿瘤细胞的生长及浸润；Lee等的研究结果表明RLIP76在食管鳞癌组织中的表达与TNM分期有关。另Wang等 [<xref ref-type="bibr" rid="hanspub.31769-ref26">26</xref>] 在乳腺癌的研究结果表明有淋巴结转移的组织RLIP76阳性率高于未转移组织(P &lt; 0.05)。RLIP76作为一种膜转运蛋白，可将化疗药物泵出细胞，抑制药物对肿瘤细胞的灭杀。RLIP76还可介导DOX的耐药性，对DOX的抗性随着蛋白脂质体中RLIP76的量呈线性增加 [<xref ref-type="bibr" rid="hanspub.31769-ref27">27</xref>]。</p></sec><sec id="s6"><title>4. RLIP76与肿瘤靶向治疗的研究新进展</title><p>近年来，人们对RLIP76的功能意义进行了广泛的研究。由此产生的新突破帮助我们理解了它的传输和信号功能。RLIP76是一种广泛表达的具有应激防御、转运、抗凋亡、信号转导等功能的蛋白。这些特性使RLIP76在细胞采用的应激防御机制的层次结构中处于非常重要的位置。RLIP76在不同来源的恶性细胞中选择性过表达是这些细胞克服化疗和放疗诱导的氧化损伤的可能机制之一。RLIP76也被证明是许多传统化疗药物的有效转运体。如果这种转运受到抑制，就会导致药物在细胞中的积累增加，进而导致药物敏感性增强。最近的研究表明，抗体、siRNA或反义物抑制或耗尽RLIP76可导致肺癌、肾癌、黑素瘤、结肠癌和前列腺癌异种移植物的严重和持续消退，且肿瘤未见复发 [<xref ref-type="bibr" rid="hanspub.31769-ref21">21</xref>]。所有这些发现都集中于这样一个事实，即这种抑制或者耗尽RLIP76的方式可以用于临床终止癌症的生长和进展。通过RLIP76作为多药转运体的在肿瘤中的参与作用的进一步研究，未来使用RLIP76抑制作为一种新兴的癌症治疗方法的前景十分良好。</p><sec id="s6_1"><title>4.1. RLIP76消耗抑制肿瘤生长的机制研究</title><p>以往研究证明RLIP76损耗会导致异种移植的肿瘤的退化 [<xref ref-type="bibr" rid="hanspub.31769-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.31769-ref28">28</xref>] [<xref ref-type="bibr" rid="hanspub.31769-ref29">29</xref>]，但是并不能区分RLIP76功能的两种可能模型：1) RLIP76由于其具有的保护作用，是运输活动所必需的关键因素。2) 它通过与不同于其转运活性的抗凋亡信号蛋白的信号的相互作用发挥作用 [<xref ref-type="bibr" rid="hanspub.31769-ref30">30</xref>]。由于RLIP76反义细胞几乎耗尽了所有的细胞质和膜相关的RLIP76，所以这两种模型的抗肿瘤效果是相同的。为了区分这两种模型，有必要在不影响细胞总RLIP76的情况下，通过实验方法具体抑制RLIP76的转运活性。RLIP76 (aa<sup>171-185</sup>)的细胞表面表位可以被抗RLIP76 IgG和针对特定肽段产生的抗体识别，这种识别是通过缺失该肽 [<xref ref-type="bibr" rid="hanspub.31769-ref31">31</xref>] 的突变RLIP76的唯一表达而被取消的。两种抗体涂层活细胞后，包括DOX和GS-HNE在内的运输底物的细胞含量迅速增加，而RLIP76总蛋白含量保持不变。研究结果支持了RLIP76的抗凋亡和应激保护作用主要与其转运活性有关的论断。这些发现表明，RLIP76是一种独特的抗癌靶点，是一种多功能高效的多药转运体和一种对癌细胞生存至关重要的抗凋亡蛋白。RLIP76能够有效转运内源性促凋亡分子(如4HNE)的GSH偶联物以及化疗药物，为癌细胞提供生存优势。未来对其他类型细胞的研究将拓展我们通过耗尽或阻断RLIP76对肿瘤细胞生长抑制机制的认识。</p></sec><sec id="s6_2"><title>4.2. RLIP76与常规化疗药物的协同作用</title><p>目前的化疗策略使用联合治疗来克服恶性肿瘤的生长。与单一药物方案相比，使用的药物剂量较低这不仅解决了耐药问题，而且还降低了化疗毒性。目前开展了RLIP76研究，以探讨将RLIP76抑制/沉默作为治疗策略的可行性，其核心思想是通过抑制转运蛋白来抑制癌细胞的生长。Rit Vatsyayan [<xref ref-type="bibr" rid="hanspub.31769-ref30">30</xref>] 等研究了RLIP76耗尽与其他传统化疗药物，特别是已知的RLIP76底物或异体细胞的协同作用。对肺癌细胞的体外初步研究表明，与仅使用DOX相比，同时使用抗RLIP76 IgG的细胞积累了更高水平的DOX，从而发挥协同作用导致细胞死亡。抗RLIP76免疫球蛋白和阿霉素之间协同作用(CI 0.36 &#177; 0.27)大于赫赛汀和阿霉素之间的累加作用 [<xref ref-type="bibr" rid="hanspub.31769-ref31">31</xref>] (CI 0.75 &#177; 0.49)。RLIP76与其他化疗药物联合治疗可以克服癌细胞系产生的耐药机制，使其更容易受到细胞毒性的影响。</p></sec><sec id="s6_3"><title>4.3. 抑制RLIP76可增加药物敏感性</title><p>多药耐药(Multi-drug Resistance, MDR)是许多癌细胞表现出的一种特性，对大量结构不同的细胞毒性药物产生的细胞毒性作用产生耐药性，它仍然是使用药物治疗根除恶性肿瘤的主要障碍。尽管许多细胞生化机制已被确认为MDR发展的原因，但由于药物或代谢物流出的能量依赖性，MDR与细胞药物的积累减少联系最为密切。MDR积累缺陷是由MRP和Pgp等多种转运蛋白介导 [<xref ref-type="bibr" rid="hanspub.31769-ref32">32</xref>] [<xref ref-type="bibr" rid="hanspub.31769-ref33">33</xref>] [<xref ref-type="bibr" rid="hanspub.31769-ref34">34</xref>]。由于药物外排机制介导药物积累缺陷，进而转化为对药物细胞毒性作用的抗性，RLIP76作为多药转运体的功能可以预测，该蛋白的过度表达将导致对其异基因载体药物的抗性。我们报道了RLIP76介导多种化疗药物耐药作用的详细研究，包括：顺铂、美法仑、DOX、柔红霉素(DAU)、VCR、VBL、VRL、舒尼替尼和索拉非尼。RLIP76介导的对上述药物的耐药性不仅局限于一个细胞系，还涉及来自不同来源的细胞，如白血病、肺癌、前列腺癌和肾癌。RLIP76在人骨髓性白血病K562中的过度表达，对蒽环素(DOX, DAU)、长春碱类生物碱(VCR, VBL, VRL)、烷基化剂和顺铂的耐药性可高达2.5倍。与SCLC细胞相比，NSCLC细胞对DOX的抗性较高，这与RLIP76介导的DOX在NSCLC中的外溢水平较高有关。RLIP76抗体涂层通过阻断其RLIP76介导的转运使NSCLC对DOX敏感。最近的研究表明，与系膜细胞相比，Caki-2，786-O和A-498肾癌细胞系过度表达RLIP76蛋白。由于RLIP76在肾癌细胞中表达较多，与系膜细胞相比，舒尼替尼和索拉非尼的转运量增加了2.5~5.5倍。另与索拉非尼相比，舒尼替尼作为一种更为有效的激酶抑制剂，在临床上更为活跃，是RLIP76转运的较差底物 [<xref ref-type="bibr" rid="hanspub.31769-ref35">35</xref>]。综上所述，这些结果表明，RLIP76除了在正常细胞中占主导地位的GS-E转运蛋白外，还在癌细胞中起关键蛋白的作用，其抑制作用导致癌细胞对药物敏感 [<xref ref-type="bibr" rid="hanspub.31769-ref30">30</xref>]。</p></sec></sec><sec id="s7"><title>5. 研究展望</title><p>根据RLIP76的生理功能与癌细胞较正常细胞中RLIP76的过度表达的特点，我们可以预测，RLIP76的耗竭或抑制会增加癌细胞中促凋亡亲电性脂质(尤其是4HNE和GS-HNE)的积累，从而导致癌细胞凋亡和坏死而对正常细胞的影响较小。这些代谢物的积累可以在低浓度时触发增殖、分化和细胞因子反应，而在高浓度时则会引起细胞凋亡或坏死。由于药物在细胞内的积累的增加，RLIP76的耗竭或抑制将增加癌细胞对化疗药物的敏感性。此外，抑制RLIP76可通过促凋亡亲电性脂质积累增加癌细胞的放射敏感性。相关研究显示，RLIP76在不影响正常细胞的情况下可抑制肾脏肿瘤血管生成和VEGF表达 [<xref ref-type="bibr" rid="hanspub.31769-ref17">17</xref>]，是一种非常理想的治疗肾癌的药物。并且动物实验已经证明了RLIP76的敲除对小鼠植入肿瘤的阻断效应 [<xref ref-type="bibr" rid="hanspub.31769-ref17">17</xref>]，这也为RLIP76相关药物的临床试验的可行性提供了证据。</p><p>因此，RLIP76治疗在未来可能是一种更加安全、高效且常用的方式，具有良好的临床前景。探究和阐述RLIP76的完整分子结构和开发其抑制剂是未来的重要研究方向。与此同时，人类使用剂量的标准化、给药途径、器官特异性和生物利用度也需要研究机构进行进一步探索和研究。</p></sec><sec id="s8"><title>文章引用</title><p>刘 东,毛 艺,马雅楠,岳少宇. RLIP76在肿瘤靶向治疗的研究进展Research Progress of RLIP76 in Targeted Therapy of Tumor[J]. 临床医学进展, 2019, 09(08): 978-985. https://doi.org/10.12677/ACM.2019.98149</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.31769-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Wurtzel, J.G., Lee, S., Singhal, S.S., et al. (2015) RLIP76 Regulates Arf6-Dependent Cell Spreading and Migration by linking ARNO with Activated R-R as at Recycling Endosomes. Biochemical and Biophysical Research Communications, 467, 785-791. &lt;br&gt;https://doi.org/10.1016/j.bbrc.2015.10.064</mixed-citation></ref><ref id="hanspub.31769-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">https://asia.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000017797;r=18:9475009-9538114</mixed-citation></ref><ref id="hanspub.31769-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Awasthi, S., Cheng, J., Singhal, S.S., Saini, M.K., Pandya, U., Pikula, S., et al. (2000) Novel Function of Human RLIP76: ATP-Dependent Transport of Glutathione-Conjugates and Doxorubicin. Biochemistry, 39, 9327-9334.  
&lt;br&gt;https://doi.org/10.1021/bi992964c</mixed-citation></ref><ref id="hanspub.31769-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Awasthi, S., Singhal, S.S., et al. (2008) RLIP76 and Cancer. Clinical Cancer Research, 14, 4372-4377.  
&lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-08-0145</mixed-citation></ref><ref id="hanspub.31769-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Q., Wang, J.Y., Zhang, X.P., Lv, Z.W., Fu, D., Lu, Y.C., et al. (2013) RLIP76 Is over-Expressed in Human Glioblastomas and Is Required for Proliferation, Tumorigenesis and Suppression of Apoptosis. Carcinogenesis, 34, 916-926. &lt;br&gt;https://doi.org/10.1093/carcin/bgs401</mixed-citation></ref><ref id="hanspub.31769-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Q., Qian, J., Wang, J.Y., Luo, C., Chen, J., Hu, G., et al. (2013) Knockdown of RLIP76 Expression by RNA Interference Inhibits Invasion, Induces Cell Cycle Arrest, and Increases Chemosensitivity to the Anticancer Drug Temozolomide in Glioma Cells. Journal of Neuro-Oncology, 112, 73-82. &lt;br&gt;https://doi.org/10.1007/s11060-013-1045-2</mixed-citation></ref><ref id="hanspub.31769-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Wang, W., Liu, J., Qi, J., et al. (2016) Downregulation of RLIP76 Is Associated with Vincristine Resistance in Human Colorectal Cancer HCT-8/VCR Cells. International Journal of Oncology, 49, 1505-1512.  
&lt;br&gt;https://doi.org/10.3892/ijo.2016.3672</mixed-citation></ref><ref id="hanspub.31769-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Singhal, S.S., Awasthi, Y.C. and Awasthi, S. (2006) Regression of Melanoma in a Murine Model by RLIP76 Depletion. Cancer Research, 66, 2354-2360. &lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-05-3534</mixed-citation></ref><ref id="hanspub.31769-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Singhal, S.S., Yadav, S., Drake, K., Singhal, J. and Awas-thi, S. (2008) Hsf-1 and POB1 Induce Drug-Sensitivity and Apoptosis by Inhibiting Ralbp1. Journal of Biological Chemistry, 283, 19714-19729.  
&lt;br&gt;https://doi.org/10.1074/jbc.M708703200</mixed-citation></ref><ref id="hanspub.31769-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Cheng, J., Sharma, R., Yang, Y., et al. (2001) Accelerated Metabo-lism and Exclusion of 4-Hydroxy-Nonenal through Induction of RLIP76 and hGST5.8 Is an Early Adaptive Response of Cells to Heat and Oxidative-Stress. Journal of Biological Chemistry, 276, 41213-41223. &lt;br&gt;https://doi.org/10.1074/jbc.M106838200</mixed-citation></ref><ref id="hanspub.31769-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Awasthi, S., Singhal, S.S., Yadav, S., Singhal, J., Drake, K., Nadkar, A., et al. (2005) RLIP76 Is a Major Determinant of Radiation-Sensitivity. Cancer Research, 65, 6022-6028. &lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-05-0968</mixed-citation></ref><ref id="hanspub.31769-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Awasthi, S., Hallene, K.L., Fazio, V., Singhal, S.S., Cu-cullo, L., Awasthi, Y.C., et al. (2005) RLIP76, a Non-ABC Transporter, and Drug Resistance in Epilepsy. BMC Neu-roscience, 6, 61. &lt;br&gt;https://doi.org/10.1186/1471-2202-6-61</mixed-citation></ref><ref id="hanspub.31769-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Awasthi, S., Singhal, S.S., Sharma, R., Zimniak, P. and Awasthi, Y.C. (2003) Transport of Glutathione-Conjugates and Chemotherapeutic Drugs by RLIP76: A Novel Link between G-Protein and Tyrosine-Kinase Signaling and Drug-Resistance. International Journal of Cancer, 106, 635-646. &lt;br&gt;https://doi.org/10.1002/ijc.11260</mixed-citation></ref><ref id="hanspub.31769-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Awasthi, S., Cheng, J., Singhal, S.S., Sharma, R., Pandya, U., Singh, S.V., et al. (2001) Functional Reassembly of Xenobiotic-Transport from the N-Terminal and C-Terminal Domains of RLIP76 and Identification of ATP-Binding Sequences. Biochemistry, 40, 4159-4168. &lt;br&gt;https://doi.org/10.1021/bi002182f</mixed-citation></ref><ref id="hanspub.31769-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Singhal, J., Singhal, S.S., Yadav, S., Warnke, M., Yacoub, A., Dent, P., et al. (2008) RLIP76 in Defense of Radiation and Chemical-Poisoning. International Journal of Radiation Oncology, Bi-ology, Physics, 72, 553-561.  
&lt;br&gt;https://doi.org/10.1016/j.ijrobp.2008.06.1497</mixed-citation></ref><ref id="hanspub.31769-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Singhal, S.S., Yadav, S., Singhal, J., Sahu, M., Sehrawat, A. and Awasthi, S. (2008) Diminished Drug Transport and Augmented Radiation Sensitivity Caused by Loss of RLIP76. FEBS Letters, 582, 3408-3414.  
&lt;br&gt;https://doi.org/10.1016/j.febslet.2008.09.001</mixed-citation></ref><ref id="hanspub.31769-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Singhal, S.S., Singhal, J., Figarola, J., Horne, D. and Awasthi, S. (2015) RLIP76 Targeted Therapy for Kidney Cancer. Pharmaceutical Research, 32, 3123-3136. &lt;br&gt;https://doi.org/10.1007/s11095-015-1723-1</mixed-citation></ref><ref id="hanspub.31769-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Hu, Y. and Mivechi, N.F. (2003) HSF-1 Interacts with Ral-Binding-Protein 1 in a Stress-Responsive, Multi-Protein Complex with HSP90 in Vivo. Journal of Biological Chemistry, 278, 17299-17306.  
&lt;br&gt;https://doi.org/10.1074/jbc.M300788200</mixed-citation></ref><ref id="hanspub.31769-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Singhal, S.S., Yadav, S., Drake, K., Singhal, J. and Awasthi, S. (2008) Hsf-1 and POB1 Induce Drug-Sensitivity and Apoptosis by Inhibiting Ralbp1. Journal of Biological Chemistry, 283, 19714-19729.  
&lt;br&gt;https://doi.org/10.1074/jbc.M708703200</mixed-citation></ref><ref id="hanspub.31769-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Singhal, S.S. and Awasthi, S. (2006) Glutathione-Conjugate Transport and Stress-Response Signaling: Role of RLIP76. In: Awasthi, S., Ed., Toxicology of Glutathione S-Transferases, CRC Press, Boca Raton, FL, 231-256.</mixed-citation></ref><ref id="hanspub.31769-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Vatsyayan, R. and Chaudhary, P. (2009) Role of RLIP76 in Doxorubicin Resistance in Lung Cancer. International Journal of Oncology, 34, 1505-1511. &lt;br&gt;https://doi.org/10.3892/ijo_00000279</mixed-citation></ref><ref id="hanspub.31769-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Awasthi, S., Sharma, R., Singhal, S.S., Zimniak, P. and Awasthi, Y.C. (2002) RLIP76, a Novel Transporter Catalyzing ATP-Dependent Efflux of Xenobiotics. Drug Metabolism &amp; Disposition, 30, 1300-1310. 
&lt;br&gt;https://doi.org/10.1124/dmd.30.12.1300</mixed-citation></ref><ref id="hanspub.31769-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">郭晓峰, 刘高峰, 李保田, 杨鲲鹏, 张勇, 刘艳, 李丹丹, 李东方, 崔素娟. RLIP76和VEGF在食管鳞癌组织中的表达及临床意义[J]. 临床肿瘤学杂志, 2018, 23(4): 330-334.</mixed-citation></ref><ref id="hanspub.31769-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">潘海霞, 白义凤, 胡洪林. RLIP76在调节小细胞肺癌多药耐药中的作用及临床意义[J]. 中华肿瘤杂志, 2015, 37(4): 266-271.</mixed-citation></ref><ref id="hanspub.31769-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Wang, W., Liu, J., Qi, J., et al. (2016) RLIP76 Increases Apoptosis through Akt/mTOR Signaling Pathway in Gastric Cancer. Oncology Reports, 36, 2216-2224. &lt;br&gt;https://doi.org/10.3892/or.2016.5043</mixed-citation></ref><ref id="hanspub.31769-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Wang, C.Z., Yuan, P., Xu, B., et al. (2015) RLIP76 Expression as a Prognostic Marker of Breast Cancer. European Review for Medical and Pharmacological Sciences, 19, 2105-2111.</mixed-citation></ref><ref id="hanspub.31769-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Singhal, S.S., Sehrawat, A., Metha, A., Sahu, M. and Awasthi, S. (2009) Functional Reconstitution of RLIP76 Catalyzing ATP-Dependent Transport of Glutathione-Conjugate. International Journal of Oncology, 34, 191-199.</mixed-citation></ref><ref id="hanspub.31769-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Singhal, S.S., Singhal, J., Yadav, S., Dwivedi, S., Boor, P., Awasthi, Y.C., et al. (2007) Regression of Lung and Colon Cancer Xenografts by Depleting or Inhibiting RLIP76. Cancer Research, 67, 4382-4389. 
&lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-06-4124</mixed-citation></ref><ref id="hanspub.31769-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Singhal, S.S., Roth, C., Leake, K., Singhal, J., Yadav, S. and Awasthi, S. (2009) Regression of Prostate Cancer Xenografts by RLIP76 Depletion. Biochemical Pharmacology, 77, 1074-1083. &lt;br&gt;https://doi.org/10.1016/j.bcp.2008.11.013</mixed-citation></ref><ref id="hanspub.31769-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Vatsyayan, R. and Rao Lelsani, P.C. (2010) RLIP76: A Versatile Transporter and an Emerging Target for Cancer Therapy. Biochemical Pharmacology, 79, 1699-1705. &lt;br&gt;https://doi.org/10.1016/j.bcp.2010.01.016</mixed-citation></ref><ref id="hanspub.31769-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Yadav, S., Singhal, S.S., Singhal, J., Wickramarachchi, D., Kuntson, E., Albrecht, T.B., et al. (2004) Identification of Membrane-Anchoring Domains of RLIP76 Using Deletion Mutants Analyses. Biochemistry, 43, 16243-16253.  
&lt;br&gt;https://doi.org/10.1021/bi0482811</mixed-citation></ref><ref id="hanspub.31769-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Choudhuri, S. and Klaassen, C.D. (2006) Structure, Function, Expression, Genomic Organization, and Single Nucleotide-Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux Transporters. International Journal of Toxicology, 25, 231-259. &lt;br&gt;https://doi.org/10.1080/10915810600746023</mixed-citation></ref><ref id="hanspub.31769-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Higgins, C.F. (2007) Multiple Molecular Mechanisms for Mul-tidrug-Resistance Transporters. Nature, 446, 749-757.  
&lt;br&gt;https://doi.org/10.1038/nature05630</mixed-citation></ref><ref id="hanspub.31769-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Sharom, F.J. (2008) ABC Multidrug-Transporters: Structure, Function and Role in Chemo-Resistance. Pharmacogenomics, 9, 105-127. &lt;br&gt;https://doi.org/10.2217/14622416.9.1.105</mixed-citation></ref><ref id="hanspub.31769-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Singhal, S.S., Sehrawat, A., Sahu, M., Singhal, P., Vatsyayan, R., Lelsani, P.C., et al. (2010) RLIP76 Transports Sunitinib and Sorafenib and Mediates Drug Resistance in Kidney Cancer. International Journal of Cancer, 126, 1327-1338. 
&lt;br&gt;https://doi.org/10.1002/ijc.24767</mixed-citation></ref></ref-list></back></article>